Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ferric derisomaltose for mobility recovery after hip fracture surgery in older adults
2024-515116-42-00Phase 4Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Jun 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferric derisomaltose in hip fracture (2 arms), sponsored by Capital Region of Denmark. Primary endpoint: Primary: New Mobility Score recovery at 6 weeks. Planned start Jun 2025; status: authorised.
02
Drugs
ferric derisomaltose
03
Conditions
hip fracture
Beyond the preview
Go deeper on 2024-515116-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515116-42-00.